Genaera ends Lomucin, squalamine trials

GENR discontinued studies of Lomucin talniflumate for cystic fibrosis and squalamine lactate to treat prostate cancer. The decision to end the Phase II trial of Lomucin, an orally absorbed antagonist of calcium-activated chloride channel (gob-5), came after a DMC said there was no additional benefit to further enrollment in the study. GENR also said it ended the investigator-led Phase II trial of squalamine because of a lack of recent enrollment and delays in restarting the study at a new site. In January, GENR discontinued development of squalamine, a synthetic small molecule anti-angiogenic aminosterol, for wet age-related macular degeneration (AMD) after data from a Phase II trial showed the compound was unlikely to improve vision with the speed or frequency necessary to compete with marketed treatments. GENR said it has no plans to pursue further development of either compound. ...